Brought to you by 
Therabel to market Loramyc and Setofilm in Europe
16 Apr 2012
Executive Summary
Following the collapse of its European joint venture with SpePharm Holding BV, BioAlliance Pharma SA (mainly oncology and infectious disease drug candidates) has found a new partner for Loramyc (miconazole) in Europe--spec pharma Therabel Pharma NV Holding, which will have exclusive rights to market the antifungal in addition to BioAlliance's anti-emetic Setofilm (ondansetron). Therabel's newly created division Therabel Hopital Pharma will be responsible for marketing the drugs in France.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Therabel to market Loramyc and Setofilm in Europe
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice